00:42:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-01-10 Årsstämma 2024
2023-10-11 Bokslutskommuniké 2023
2023-07-07 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2


ListaFirst North Stockholm
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.
2022-04-26 08:00:00

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Ivermectin 10mg/g Cream, also known by its brand name Soolantra®. Ivermectin Cream is a topical treatment indicated for the treatment of inflammatory lesions of rosacea in adult patients.

Newbury Pharmaceuticals is also pleased to announce the successful enlargement of the portfolio with the addition of Azelastine+Fluticasone, also known by its brand name Dymista®. Azelastine+Fluticasone is indicated for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

“The two new products are strengthening our existing portfolio. With these new additions, we will increase the number of launches in the coming years with two competitive treatments.” says Mr Lars Minor CEO of Newbury.

Newbury currently has twenty-nine (29) products in its portfolio with planned launches over the coming years. The first launch has taken place with more products to follow.
Regulatory filling of the two new products will take place during the next few years, and we aim to be among the first to launch these medicines in the Nordics where the total current annual value of the market for these two products is estimated to be 24 MEUR according to DLMI Nordic Pharma Insights.